**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | LAMIVUDINE 150 mg & ZIDOVUDINE 300 mg TABLETS | | REF. NO: NDQD201508090 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each film coated tablet contains : Lamivudine U.S.P. 150 mg and Zidovudine U.S.P 300 mg. | |
| **BATCH NO.:** LZ1514011-A | **PRESENTATION:** | White coloured, film coated, caplet-shaped tablets embossed with 'C60' on one face, but plain on the other, packed in a white plastic multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Apr. 2014 | **MANUFACTURER:** | Aurobindo Pharma Limited. | |
| **EXP. DATE:** Mar. 2017 | **ADDRESS:** | Unit III, Survey No. 313, Bachupally Village, Quthubullapur Mandal, Ranga Reddy District (A.P.), INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC:HPLC | Adopted In-House Method | RT of the component peaks in the assay sample preparation correspond to those in the assay standard preparation | Super-imposable peaks at RT 2.8 and 3.7 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Lamivudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 100.1% (RSD = 1.7%; n = 6) | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | Zidovudine | **COMPLIES:COMPLIES** |
| **Dissolution** | HPLC:HPLC | Adopted In-House Method | No tablet less than 80.0% [n=6] | 99.4% (RSD = 1.6%; n = 6) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Lamivudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 95.1% (RSD = 1.0%; n = 9) | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | Zidovudine | **COMPLIES:COMPLIES** |
| **Assay** | HPLC:HPLC | Adopted In-House Method | 90.0 - 110.0% | 94.3% (RSD = 1.0%; n = 9) | **COMPLIES:COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | DATE: |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-05-2015 |